多西紫杉醇联合吉西他滨治疗晚期非小细胞肺癌的临床观察

目的:观察非铂类药物多西紫杉醇(艾素)和吉西他滨(泽菲)联合治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:37例NSCLC给予泽菲1 000mg/m2,第1天和第8天静脉滴注30min,艾素75mg/m2,第8天静脉滴注1h,21d为一个周期,至少治疗2个周期。结果:全组33例可评价疗效,CR 1例,PR 11例,总有效率为39.4%(CR+PR),SD45.5%(15/33),PD18.2%(6/33),中位生存期为11个月,疾病进展时间为6.5个月;1年生存率为48.5%(16/33)。不良反应主要是骨髓抑制,其中Ⅲ~Ⅳ度白细胞下降有31.4%,Ⅲ~Ⅳ度血小板下降有23.5%;非血液学毒性表现为恶心及呕吐,Ⅰ~Ⅱ度有23.1%,无Ⅲ~Ⅳ度恶心及呕吐。结论:多西紫杉醇联合吉西他滨对于晚期NSCLC疗效较理想,不良反应较低,对于提高生活质量有意义,是可以替代铂类药物的有效方案。

The Clinical Observation of Docetaxel Combined with Gemcitabine in the Treatment of Advanced Patients with Non-small-cell Lung Cancer

Objective：To estimate the efficacy, toxicity and side effects of the combinations of gemcitabine and docetaxel in the treatment of advanced patients with non-small cell lung cancer （NSCLC）. Methods： 37 advanced patients with NSCLC diagnosed by pathology or cytology were enrolled into the study. The patients received gemcitabine 1 000 mg/m^2 on the 1st,8th day and docetaxel 75mg/m^2 in the 8th day. Both regiments had 21-day cycle, three weeks repeated and the efficacy was estimated after 2 periods. Results： The overall response rate was 39. 4% （12/33）, SD 45. 5% （ 15/33）, and PD18. 2%（6/33）. The median overall survival of the whole group was 11 months,TTP was 6. 5 months, the survival rate for 1-year survival time was 48. 5%. The Ⅲ-Ⅳ leucopenia was31.4%, but the Ⅲ-Ⅳ thromasthenia was 23. 5%, nausea and vomiting were mild to moderate. Conclusion： Gemcitabine plus docetaxel is an active and well-tolerated regimen and represents an option for treatment of the patients with advanced NSCLC.